Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: A post-hoc analysis of the Thai phase 3 efficacy trial RV 144

by Merlin L. Robb, Supachai Rerks-Ngarm, Sorachai Nitayaphan, Punnee Pitisuttithum, Jaranit Kaewkungwal, Prayura Kunasol, Chirasak Khamboonruang, Prasert Thongcharoen, Patricia Morgan, Michael Benenson, Robert M. Paris, Joseph Chiu, Elizabeth Adams, Donald Francis, Sanjay Gurunathan, Jim Tartaglia, Peter Gilbert, Don Stablein, Nelson L. Michael, Jerome H. Kim
Published 2018

The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope

by Mark S. De Souza, Silvia Ratto-Kim, Weerawan Chuenarom, Alexandra Schuetz, Somsak Chantakulkij, Bessara Nuntapinit, Anais Valencia-Micolta, Doris Thelian, Sorachai Nitayaphan, Punnee Pitisuttithum, Robert M. Paris, Jaranit Kaewkungwal, Nelson L. Michael, Supachai Rerks-Ngarm, Bonnie Mathieson, Mary Marovich, Jeffrey R. Currier, Jerome H. Kim, Supamit Chunsuttiwat, Nakorn Premsri, Chawetsan Namwat, Prayura Kunasol, Prasert Thongcharoen, Chirasak Khamboonruang, Valai Bussaratid, Wirach Maek-a-nantawat, Jittima Dhitavat, Pravan Suntharasamai, Swangjai Pungpak, Siriwan Vanijanonta, Jaranit Kaewkunwal, Amnat Khamsiriwatchara, Pawinee Jarujareet, Chirapa Easmila, Suchana Tabprasit, Viseth Ngauy, Robert Paris, Michael Benenson, Patricia Morgan, Arthur Brown, Mark De Souza, Rapee Trichavaroj, Nusara Thaitawat, Kanyasiri Kongnonkok, Boot Keawboon, Yuwadee Phuang-Ngern, Susan Mason, Sanjay Gurunathan, Jim Tartaglia, John G. McNeil, Robin Harkness, Claude Meric, Lynn Baglyos, Raphaelle El Habib, Don Francis, Carter Lee, Elizabeth Adams, Merlin L. Robb, Mark Milazzo, Amy Bolen, Beryl Wessner, Jeffrey Currier, Deborah L. Birx, Don Stablein, Terry Germanson, Len Dally, Jean Louis Excler, Jeffrey Berenberg
Published 2018